Cancer

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

PRINCETON, NJ / ACCESSWIRE / December 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical…

1 year ago

Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL

Topline Data from a Registration-Enabling Phase 3 Clinical Trial is Due Later This Month.CHATHAM, NJ / ACCESSWIRE / December 14,…

1 year ago

Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ: AMAM), today announced that the Company…

1 year ago

FDA Breakthrough Device using Optical Spectroscopy was Found to Significantly Increase Physicians’ Detection of Skin Cancer

MIAMI--(BUSINESS WIRE)--DermaSensor Inc., the pioneer of the first point-and-click skin cancer detection device for primary care physicians, announces the publication…

1 year ago

FDA Breakthrough Device using Optical Spectroscopy was Found to Significantly Increase Physicians’ Detection of Skin Cancer

MIAMI--(BUSINESS WIRE)--DermaSensor Inc., the pioneer of the first point-and-click skin cancer detection device for primary care physicians, announces the publication…

1 year ago

Lynx.MD and Baptist Health Innovations Collaborate to Advance Medical Research and Development

Initiative enhances Baptist Health South Florida's efforts in medical innovation for advanced research and collaborative development.PALO ALTO, CA / ACCESSWIRE…

1 year ago

SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET

NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a…

1 year ago

Research for the Treatment of a ‘Black Sheep’ Cancer Moves to Human Clinical Trials

With $3.5 million in funding from the GI Research Foundation, a team at the MD Anderson Cancer Center explores a…

1 year ago

Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer

VISTA Blocking KVA12123 Monoclonal Antibody (mAb) Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse Events…

1 year ago